Nowadays the most widely used antidepressants are selective serotonin reuptake inhibitors (SSRI) or noradrenaline reuptake inhibitors (NRI), however, these take four to eight weeks to exert their effects and each drug is efficacious only in 60e70% of patients. In an attempt to improve the efficacy of antidepressants, new drugs that also modify dopamine levels are being developed. The aim of this study was to investigate the impact of L-DOPA administration on the effect elicited by antidepressants on serotonergic and noradrenergic neurotransmission. To this end, single-unit extracellular recordings of the noradrenergic nucleus, locus coeruleus (LC), and the serotonergic nucleus, dorsal raphe (DRN) combined with behavioural approaches were performed. L-DOPA did not modify the basal neuronal activity in either the LC or the DRN or induce any change in the modified forced swimming test. However, L-DOPA enhanced the neuronal response to reboxetine in the LC and increased its antidepressant-like effects but counteracted the effect of fluoxetine on neurons in the LC and decreased its antidepressant-like effect. The sensitivity of neurons in the DRN to reboxetine and fluoxetine was not altered by the administration of L-DOPA. Taken together, these results indicate that L-DOPA modifies the effect of SSRI and NRI antidepressants in opposing ways.
Introduction
Major depression is a recurrent or chronic mood disorder that results in impaired psychosocial function. Patients who fail to reach remission have an increased tendency to relapse. In industrialised societies, depression affects approximately 15% of the general population (Kessler et al., 2007) . The most commonly used antidepressants are the selective serotonin reuptake inhibitors (SSRI) followed by the noradrenaline reuptake inhibitors (NRI), which modulate serotonergic and/or noradrenergic neurotransmission, respectively. Both groups of drugs are similar in terms of onset of antidepressant effect and efficacy, taking four to eight weeks to exert their antidepressant effect and being efficacious in only 60e 70% of patients. Several efforts to increase the efficacy have been made using concomitantly an antidepressant with a substance from another drug class, among others those that act on the dopaminergic system (Bauer et al., 2010; Blier, 2008; Papakostas, 2006; Vieta and Colom, 2011) .
The involvement of the dopaminergic system in the etiopathology of depression is supported by several evidences. Lower concentrations of homovanilic acid, a chief metabolite of dopamine, have been reported in cerebrospinal fluid, plasma, serum and urine of depressed patients (Engstrom et al., 1999; Hamner and Diamond, 1996; Lambert et al., 2000) . In addition, dopamine receptor and transporter levels are decreased in depressed patients (Klimek et al., 2002; Meyer et al., 2001) , and pathologies that present low concentrations of dopamine, such us Parkinson's disease, have a high prevalence of depressive episodes (Hemmerle et al., 2012; Lieberman, 2006) . Clinical studies have indicated that dopaminergic receptor agonists are effective in the treatment of otherwise treatment-resistant depression patients (Cassano et al., 2005 (Cassano et al., , 2004 Dhillon et al., 2008; Inoue et al., 2010; Kapur and Mann, 1992; Schulte-Herbruggen et al., 2012) .
Previous studies have demonstrated that both SSRI and NRIs inhibit neuronal activity in both the locus coeruleus (LC) and the dorsal raphe nucleus (DRN) (Miguelez et al., 2009 (Miguelez et al., , 2011b . Interestingly, depletion of dopamine concentrations altered neuronal Abbreviations: DRN, dorsal raphe nucleus; i.p, intraperitoneal; i.v., intravenous; L-DOPA, L-3,4-dihydroxyphenylalanine; LC, locus coeruleus; mFST, modified forced swimming test; SSRI, selective serotonin reuptake inhibitors; PD, Parkinson's disease.sensitivity to those antidepressants. It was demonstrated that when dopamine is absent, the SSRI, fluoxetine, is less effective in inhibiting noradrenergic neurons, whereas the NRI, reboxetine, is more effectively inhibiting serotonergic neurons (Miguelez et al., 2011b) . SSRIs and NRIs are often co-administered with the dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) since parkinsonian patients frequently suffer depressive episodes.
L-DOPA is transformed into dopamine that as endogenous neurotransmitter can act on dopaminergic receptors. Alternatively, it can also be converted into noradrenaline, bind with high affinity a 2 -adrenoceptors (Alachkar et al., 2010) or be stored by serotonergic afferents (Arai et al., 1994 (Arai et al., , 1995 Mercuri and Bernardi, 2005) . As L-DOPA can act via various mechanisms depending on the neurotransmission system, it is likely that its administration differently affects the antidepressant efficacy of SSRI or NRI.
This study aims to investigate how L-DOPA influences the effect of antidepressants. The elucidation of such interaction can help to design new strategies for the treatment of depression, especially for treatment-resistant cases or drug-naïve patients that require a fast therapeutic answer. To accomplish this, both electrophysiological and behavioural approaches were used. Our results show that L-DOPA augments the effects of reboxetine but attenuates the effects of fluoxetine.
Materials and methods

Animals
Male Sprague-Dawley rats (weighing 250e400 g) were housed under a 12:12 h light:dark cycle and given ad libitum access to food and water. Every effort was made to minimise animal suffering and the number of animals used. All experimental protocols were reviewed and approved by the Local Committee for Animal Experimentation at the University of the Basque Country and the University of Cadiz. All of the experiments were performed in compliance with the European Community Council Directive on "The Protection of Animals Used for Experimental and Other Scientific Purposes" (86/609/EEC) and with Spanish Law (RD 1201 (RD /2005 for the care and use of laboratory animals. All rats were experimentally naïve and were used only once. Behavioural tests were performed between 9:00 and 14:00 h.
Electrophysiological procedures
Single-unit extracellular recordings of LC and DRN neurons were performed as previously described (Miguelez et al., 2011b) . The animals were anaesthetised with chloral hydrate (400 mg/kg, intraperitoneally, i.p.). Each rat was placed in a stereotaxic frame, and its body temperature was maintained at approximately 37 C for the entire experiment. To record from the LC, the rat's head was oriented at 15 to the horizontal plane (i.e., nose down). To record from the DRN, a ligature was applied, and the sagittal sinus was subsequently cut. Then, a recording electrode was lowered into the LC (relative to lambda: AP: À3.7 mm, ML: þ1.1 mm, DV: À5.5 to À6.5 mm) or the DRN (relative to lambda: AP: þ1.0 mm, ML: 0 mm, DV: À4.5 to À6.0 mm). Neurons in the LC were identified by the following criteria: 1) spontaneous activity with a regular rhythm and a firing rate between 0.5 and 5 Hz; 2) characteristic spikes with a long-lasting, positiveenegative waveform; and 3) a biphasic excitationeinhibition response to pressure that was applied to the contralateral hind paw (paw pinch). Burst-firing onset and end were defined as the concurrence of two spikes with an interspike interval between 0.08 and 0.16 s, respectively (Dawe et al., 2001) . Serotonergic neurons in the DRN were identified by the following criteria: 1) wide-duration action potentials that occur between 1e2 ms positiveenegative spikes; 2) a regular rhythm; and 3) a slow firing rate (0.5e3 Hz).
The firing patterns were analysed offline with a script file using the computer software Spike2, and the following parameters were calculated: the firing rate, the coefficient of variation (the percentage ratio of standard deviation to the mean interval value of an interspike time-interval histogram), the percentage of spikes in burst and the percentage of cells that exhibited burst firing and responded to intravenous drug administration. Only one cell was studied per animal when any drug was administered.
At the end of each experiment, Chicago Sky Blue 6B (SigmaeAldrich, Spain) was used to mark the recording site while a 5 mA cathodic current was passed through the recording electrode for 10 min. The animals were deeply anaesthetised and transcardially perfused with 4% ice-cold paraformaldehyde that had been prepared in 0.1 M phosphate buffer. The brains were removed and transferred to a 25% sucrose solution until they sank. Coronal 40-mm sections were cut using a freezing microtome (HM 430, Microm International, Germany), mounted on gelatinised glass and stained with neutral red. For all of the experiments that were included in this study, the location of the recording sites was verified as being within the LC or the DRN.
Modified forced swimming test
The modified forced swimming test (mFST) was used to determine the effect of administering L-DOPA on the antidepressant-like effects of reboxetine and fluoxetine. This test is commonly used by numerous laboratories worldwide, being considered the most widely used animal test predictive of antidepressant action (Alba-Delgado et al., 2013; Bravo et al., 2012; Cryan et al., 2005) . The mFST was conducted as previously described (Detke et al., 1995) . Each rat was individually placed in a Pyrex cylinder (20 Â 46 cm) that had been filled to a depth of 30 cm with water at 23e25 C. The water was changed for each animal. After 15 min, the rat was removed, dried and returned to its home cage. Twenty-four hours after its first exposure, the animal was again placed in the cylinder for 5 min and its behaviour was monitored from above by a video camera. A highly trained observer who was blind to the treatment subsequently evaluated the predominant behaviour that occurred during each 5-s period of the 300-s test. The following behaviours were measured: climbing behaviour, defined as upward-directed movements of the forepaws that usually occurred along the side of the swim chamber; swimming behaviour, defined as movement throughout the chamber including crossing across quadrants of the cylinder; and immobility, characterised by a lack of activity other than the amount required to keep the rat's head above the water. Drug injections were administered i.p. three times at 1 h, 5 h and 23.5 h prior to the test session.
An increase in swimming behaviour has previously been observed in response to antidepressants that enhance serotonergic neurotransmission (e.g., SSRIs), whereas an increase in climbing behaviour has been observed in response to antidepressant drugs that selectively affect noradrenergic transmission (Detke et al., 1995) . A reduction in immobility during the mFST was considered to indicate antidepressant-like activity.
Locomotor activity
To explore the possible influence of motor activity levels in the results of the mFST, spontaneous locomotion was assessed in the rats. Similar to the protocol of administration that was used in the mFST, naïve animals were injected three times at 23.5 h, 5 h, and 1 h before the test. Locomotor activity was assessed using an openfield (20 Â 30 Â 30 mm) bar system that was provided by LETICA Science Instruments (LSI Letica Ò , LE 886, Panlab S.L., Cornellá, Barcelona). The floor consisted of a stainless steel grid that was constructed from 28 bars of 3 mm of diameter each one; the bars were associated with a detector that sensed changes in electric resistance. Each animal was placed in the chamber and allowed to explore freely. The animal's activity was monitored for 5 min, and data on horizontal activity were collected.
Drugs
Chloral hydrate, reboxetine mesylate (Tocris), L-DOPA (L-3,4-dihydroxyphenylalanine methyl ester hydrochloride), benserazide-HCl (Sigmae Aldrich), and fluoxetine hydrochloride (courtesy of FAES FARMA) were all used in this study. Chloral hydrate, L-DOPA and benserazide were prepared in 0.9% saline; fluoxetine and reboxetine were prepared in distilled water.
Statistical analysis
The data were expressed as the mean values AE S.E.M., and the level of significance was set at p < 0.05. For the electrophysiological data, all changes in the firing rate are expressed as percent change from the baseline firing rate, which was defined as the mean firing rate during the 3 min prior to drug injection. Any response to the administration of drugs was evaluated according to doseconcentrationeeffect curves that were non-linearly fitted to a logistic threeparameter equation as previously described (Miguelez et al., 2009 (Miguelez et al., , 2011b . The effect of L-DOPA was assessed by using a paired Student's t-test to compare all electrophysiological parameters except for neurons with bursts and the frequency of neuronal responses, which were analysed using a c 2 test. For doseeeffect curves with one or two independent variables, one-way or two-way ANOVAs were used, respectively. Any ANOVA that showed significance was followed by the Bonferroni post hoc test. In the mFST and the locomotor activity test, the effects of L-DOPA, reboxetine or fluoxetine were compared to the saline group, and an unpaired Student's t-test was used to compare two groups; alternatively, a one-way ANOVA followed by the Dunnett test was used. To study the interactions between drugs, a statistical analysis was performed using a two-way ANOVA. The factors of variance were L-DOPA treatment and reboxetine or fluoxetine treatment. To study the effect of co-administering L-DOPA and an antidepressant a one-way ANOVA was used followed by the Dunnett test. For clarity, all two-way ANOVAs have been summarised in Table 2 .
Results
The administration of L-DOPA does not modify the basal electrophysiological characteristics of noradrenergic neurons in the locus coeruleus or serotonergic neurons in the dorsal raphe nucleus
To study the interaction between L-DOPA and antidepressants we first characterised the effect of a single dose of L-DOPA (6 mg/kg plus 15 mg/kg of benserazide, i.p.) on the electrophysiological parameters of neurons in the LC and the DRN. This dose was selected since it has been proved to increase dopamine concentrations in intact rats (Lindgren et al., 2010) . Recordings from 24 noradrenergic neurons in the LC and 17 serotonergic neurons in the DRN were collected before and 5 min after the administration of L-DOPA (one neuron per animal). All of the cells exhibited typical electrophysiological characteristics of noradrenergic or serotonergic neurons, as described above, and were localised within the LC and the DRN, respectively.
In the LC, administering L-DOPA did not modify the firing rate (1.52 AE 0.11 Hz vs. 1.54 AE 0.12 Hz, n ¼ 24), the coefficient of variation (35 AE 3% vs. 36 AE 3%, n ¼ 22), the percentage of spikes in burst (2.00 AE 0.00% vs. 2.33 AE 0.24%, n ¼ 9), the mean number of spikes/burst (2.21 AE 0.73 vs. 2.25 AE 0.70, n ¼ 9) or the percentage of neurons with burst firing (38% vs. 38%) before and after L-DOPA, respectively. Similarly, in the DRN, administration of L-DOPA did not change the neuronal firing rate (1.71 AE 0.14 Hz and 1.67 AE 0.14 Hz, n ¼ 17) or the coefficient of variation (24 AE 2% and 24 AE 2%) before and after L-DOPA, respectively. Additionally we studied the effect of 12 mg/kg of L-DOPA in LC basal electrophysiological parameters and LC and DRN neuron basal activity recorded 60 min after 6 mg/kg of L-DOPA administration. No differences were observed in either experiment (data not shown).
Overall, L-DOPA, at the selected dosage, did not alter any basal electrophysiological parameters either in the LC or DRN.
3.2. The administration of L-DOPA enhances the effect of reboxetine and attenuates the effect of fluoxetine on noradrenergic neurons in the locus coeruleus As observed in previous studies (Miguelez et al., 2011b; Szabo and Blier, 2001) , the acute administration of reboxetine (0.025e 0.8 mg/kg, i.v.) in control rats significantly decreased the spontaneous firing activity of neurons in the LC in a dose-dependant manner (Fig. 1A) . When reboxetine treatment was preceded by the Fig. 1 . The effect of reboxetine and fluoxetine on noradrenergic neurons in the locus coeruleus of control and L-DOPA-pretreated rats. The histogram portrays the inhibitory effect of reboxetine (0.025e0.8 mg/kg, i.v.) on the firing rate of noradrenergic neurons in the LC of control (A) and L-DOPA-pretreated (6 mg/kg þ 15 mg/kg of benserazide, i.p.) (B) rats. In the same way, histograms representing the inhibitory effects of fluoxetine (2.5e20 mg/kg, i.v.) on the firing rate of noradrenergic neurons in the LC of control (C) and L-DOPA-pretreated (D) rats. The doseeresponse curves for reboxetine (C) and fluoxetine (D) on noradrenergic neurons in the LC of control and L-DOPA-injected rats. L-DOPA was administered 5 min before the antidepressant. The symbols represent the means AE S.E.M. of the percentage of reduction from the basal firing rate, and n ¼ 8, 6, 15 and 13 animals were included in the reboxetine control, the reboxetine þ L-DOPA, the fluoxetine control and the fluoxetine þ L-DOPA groups, respectively; ***: p < 0.001 and *: p < 0.05 when compared with the control group (two-way ANOVA followed by a Bonferroni post hoc test).
administration of L-DOPA, reboxetine also exerted a dose-dependant inhibitory effect on neurons in the LC (F (4,23) ¼ 46.41, p < 0.0001, one-way ANOVA) (Fig. 1B) . However, the administration of L-DOPA significantly shifted the doseeresponse curve of reboxetine to the left (Table 1 and Fig. 1E ) and decreased the ED 50 value compared to the control group (ED 50 ¼ 0.05 AE 0.01 mg/kg, n ¼ 6 vs. ED 50 ¼ 0.11 AE 0.02 mg/kg, n ¼ 5, for L-DOPA and control group, respectively, p < 0.01, unpaired Student's t-test).
The acute administration of fluoxetine (2.5e20 mg/kg i.v.) significantly inhibited spontaneous firing activity in the LC in a dose-dependant manner, as already reported (Miguelez et al., 2009) (Fig. 1C) . When the administration of fluoxetine was preceded by the administration of L-DOPA, this inhibitory effect was also observed (F (4,39) ¼ 10.69, p < 0.0001, one-way ANOVA) (Fig. 1D) ; however, the effect of fluoxetine was attenuated in this case (Table 1 and Fig. 1F ). The inhibition of neurons in the LC was significantly weaker when doses of 15 and 20 mg/kg of fluoxetine were given than in control rats (Bonferroni post hoc test, p < 0.05). The percentage of neurons in the LC that responded to fluoxetine was similar between the groups (c 2 ¼ 0.59, df ¼ 1, p > 0.05) with 71% and 81% in the control and the L-DOPA group, respectively. In conclusion, the combination of L-DOPA with reboxetine or fluoxetine either augmented or attenuated the inhibitory effect of the antidepressant on LC neurons, respectively.
3.3. The administration of L-DOPA does not change the effect of either reboxetine or fluoxetine on serotonergic neurons in the dorsal raphe nucleus
The rats were injected with 6 mg/kg of L-DOPA (together with 15 mg/kg of benserazide, i.p.) 5 min before reboxetine (0.625e60 mg/kg, i.v.) or fluoxetine (0.125e16 mg/kg, i.v.) was administered.
Administering fluoxetine alone significantly decreased the spontaneous firing activity of neurons in the DRN in a dosedependant manner, as reported previously (Czachura and Rasmussen, 2000; Miguelez et al., 2011b) . When the administration of fluoxetine was preceded by L-DOPA, fluoxetine produced an identical dose-dependant inhibitory effect (F (6,32) ¼ 50.66, p < 0.0001, one-way ANOVA), and the doseeresponse curve of fluoxetine remained the same (Table 1 and Fig. 2A ). ED 50 values were also similar between the two conditions (1.24 AE 0.23 mg/kg, n ¼ 8 for the control vs. 0.92 AE 0.13 mg/kg, n ¼ 5 for the L-DOPApretreated group, unpaired Student's t-test, p > 0.05).
In agreement with earlier studies (Linner et al., 2004; Miguelez et al., 2011b; Wong et al., 2000) reboxetine significantly decreased the spontaneous firing activity of neurons in the DRN in a dosedependant manner. When reboxetine treatment was preceded by the administration of L-DOPA, reboxetine produced a similar dosedependant inhibitory effect on these neurons (F (7,41) ¼ 20.19, p < 0.0001, one-way ANOVA). Pre-treatment with L-DOPA did not alter either the doseeresponse curves (Table 1 and Thus, administration of L-DOPA together with reboxetine or fluoxetine did not modify the effect of each antidepressant on DRN neuron activity.
Antidepressant-like effects of reboxetine and fluoxetine
To determine the range of effective doses, the antidepressantlike effects of reboxetine (2.8, 5.6 and 11.2 mg/kg, i.p.) and fluoxetine (5, 10 and 20 mg/kg, i.p.) were first studied under control conditions in the mFST.
As in Page et al. (2003) , reboxetine reduced the immobility time (F (3,31) ¼ 3.91, p < 0.05, one-way ANOVA) of the rats in a dose-dependant manner while inducing a corresponding increase in their climbing time (F (3,31) ¼ 3.27, p < 0.05, one-way ANOVA) (Fig. 3A) . In both cases, the values differed significantly from controls when 11.2 mg/kg of the drug was given (Dunnett post hoc test). The rats' swimming time was similar for all doses tested (F (3,31) ¼ 0.45, p > 0.05, one-way ANOVA). As shown in other studies (Detke et al., 1995 (Detke et al., , 1997 ) fluoxetine decreased the immobility time (F (3,23) ¼ 3.45, p < 0.05, one-way ANOVA) and increased the swimming time (F (3,23) ¼ 3.51, p < 0.05, one-way ANOVA) in a dose-dependant manner (Fig. 3B) . A post hoc Dunnett test revealed significant differences when the drugs were administered at 20 mg/kg compared with control values. The climbing time was similar for all groups (F (3,23) ¼ 0.01, p > 0.05, one-way ANOVA).
3.5. The effect of L-DOPA on the antidepressant-like effects of reboxetine and fluoxetine as assessed by the modified forced swimming test
The effects of administering L-DOPA (6 mg/kg þ 15 mg/kg benserazide, i.p.) in combination with reboxetine or fluoxetine were studied in rats that underwent the mFST. Based on the electrophysiological results, ineffective doses of reboxetine (0.7, 1.4 and 2.8 mg/kg, i.p.) and an effective dose of fluoxetine (20 mg/kg, i.p.) were used in order to study if reboxetine rendered effective and fluoxetine had a weaker effect when they were co-administered with L-DOPA.
A two-way ANOVA revealed that treatment with both reboxetine and L-DOPA had a significant effect on both immobility and climbing time. Furthermore, reboxetine also significantly affected the time the rats spent swimming (Table 1 and Fig. 4) . Subsequently, a one-way ANOVA showed that L-DOPA treatment (1.4 and 2.8 mg/kg) increased the antidepressant-like effects of reboxetine when compared with reboxetine alone. Thus, the administration of L-DOPA along with 1.4 mg/kg of reboxetine decreased the immobility of the rats (F (2,30) ¼ 4.59, p < 0.05) but did not modify their swimming (F (2,30) ¼ 0.59, p > 0.05) or climbing time (F (2,30) ¼ 2.47, p > 0.05). When a 2.8 mg/kg dose of reboxetine was given, L-DOPA caused a reduction in the immobility (F (2,30) ¼ 3.44, p < 0.05) and swimming (F (2,30) ¼ 6.45, p < 0.01) time but significantly increased the climbing time (F (2,30) ¼ 7.24, p < 0.01) during the mFST. None of these behaviours were modified by L-DOPA that was combined with a 0.7 mg/kg dose of reboxetine. A subsequent post hoc Dunnett test showed significant changes in mFST behaviours occurred when a 1.4 or 2.8 mg/kg dose of reboxetine was combined with a 12 mg/kg dose of L-DOPA (Fig. 4A, B and C) .
When fluoxetine and L-DOPA treatments were combined, a twoway ANOVA revealed that both factors significantly interacted to affect immobility in the mFST, while the swimming and climbing times were significantly modified by fluoxetine alone (Table 1 and (Fig. 5A, B and C) .
Evaluation of locomotor activity
To avoid the possibility that an enhancement of generalised motor activity could explain the changes seen in mFST-related behaviours, each antidepressant was administered alone and in combination with L-DOPA to assess its ability to alter locomotor activity in the locomotor activity chamber (Table 2) .
A two-way ANOVA revealed that both L-DOPA and reboxetine significantly affected locomotor activity (Tables 1 and 2) . A subsequent one-way ANOVA showed that the reboxetine-treated animals had significantly reduced locomotor activity compared with the saline-treated animals (F (3,33) ¼ 6.52, p < 0.01) at all doses of reboxetine. Administering L-DOPA further reduced the locomotor activity when it was given in combination with reboxetine (F (2,23) ¼ 16.43, p < 0.001 for 0.7 mg/kg of reboxetine; F (2,26) ¼ 14.31, p < 0.001 for 1.4 mg/kg of reboxetine and F (2,25) ¼ 6.22, p < 0.01 for 2.8 mg/kg reboxetine).
A two-way ANOVA also revealed that fluoxetine significantly affected locomotor activity (Table 1) . Indeed, 20 mg/kg of fluoxetine, which is a dose that has already been effective in the mFST, also decreased the locomotor activity in a statistically significant manner when compared with the saline-treated animals (unpaired Student's t-test, p < 0.001, Table 2 ). However, administering L-DOPA in combination did not modify the effect of fluoxetine alone (F (2, 27) 
This experiment demonstrated that the L-DOPA-induced effects seen in the mFST are not due to the putative locomotor effect of the drug. In combination with the antidepressants, L-DOPA enhanced the hypoactivity that was induced by the antidepressants alone rather than increasing hyperkinesia, which could mask the antidepressant-like effect observed in the mFST.
Discussion
This study demonstrates that the co-administration of L-DOPA along with an SSRI or an NRI can oppositely modify the effect of the The administration of fluoxetine (20 mg/kg, i.p.) also decreased immobility and increased swimming behaviour compared with saline-treated animals. Lower doses (5 and 10 mg/kg, i.p.) did not have a significant effect. Im: immobility; sw: swimming behaviours; and cl: climbing behaviours. The data are presented as the means AE S.E.M. of the mean counts, and 6e9 rats were included in each group. *: p < 0.05 when compared to the saline-treated group (one-way ANOVA followed by a Dunnett post hoc test). Fig. 4 . The influence of L-DOPA pre-treatment on the antidepressant-like effects of reboxetine in the modified forced swimming test. The effects of L-DOPA (6 and 12 mg/kg þ 15 mg/kg of benserazide) and reboxetine (0.7, 1.4 and 2.8 mg/kg) on the immobility (A), swimming (B) and climbing behaviour (C) of rats undergoing the modified forced swimming test were studied when the drugs were either given alone or in combination. The data are presented as the means AE S.E.M. of the mean counts, and 9e11 rats were included in each group. *: p < 0.05 and **: p < 0.01 when compared with the corresponding reboxetine-alone treatment group (Dunnett post hoc test). Fig. 5 . The influence of L-DOPA pre-treatment on the antidepressant-like effects of fluoxetine in the modified forced swimming test. The effects of L-DOPA (6 and 12 mg/kg, i.p. þ 15 mg/kg of benserazide) and fluoxetine (20 mg/kg, i.p.) on the immobility (A), swimming (B) or climbing behaviour (C) of rats undergoing the modified forced swimming test were studied when the drugs were either given alone or in combination. The data are presented as the means AE S.E.M. of the mean counts, and 9e10 rats were included in each group. **: p < 0.01 when compared with the corresponding fluoxetine-alone treatment group (one-way ANOVA followed by Dunnett post hoc test); ###: p < 0.001 when compared with the saline-treated group (unpaired Student's t-test).
antidepressants. The electrophysiological data described here indicate that L-DOPA augments the effect of reboxetine and attenuates the effect of fluoxetine in the LC. Consistent with these electrophysiological findings, pre-treatment with L-DOPA caused non-effective doses of reboxetine to become effective, while attenuating an effective dose of fluoxetine as determined by the mFST.
Significance of the electrophysiological findings
We have previously demonstrated that chronic dopaminergic denervation reduces the basal firing activity of neurons in the LC without changing the electrophysiological properties of neurons in the DRN (Miguelez et al., 2011b) . Interestingly, chronic treatment with L-DOPA has been found to reverse these changes (Miguelez et al., 2011a) , which suggests that dopamine depletion or dopaminergic agents can importantly modulate the activity of neurons in the LC. Here, we extend these results by demonstrating that acute administration of 6 mg/kg of L-DOPA does not produce any change in neuronal activity in the LC or the DRN of control animals. This was an unexpected finding because neurons in both the LC and the DRN express dopaminergic receptors (Bouthenet et al., 1987; Mansour et al., 1990 Mansour et al., , 2003 Suzuki et al., 1998; Yokoyama et al., 1994) , and dopamine and dopaminergic drugs have been shown to regulate their cellular activity (Guiard et al., 2008; Lin et al., 2008; Martin-Ruiz et al., 2001 ). In addition, L-DOPA can be also transformed into noradrenaline (Mercuri and Bernardi, 2005) which can alter neuronal activity in the LC and DRN through a 1 or a 2 adrenoceptors Aghajanian, 1980a, 1980b; Cedarbaum and Aghajanian, 1976; Clement et al., 1992; Garratt et al., 1991; Pudovkina and Westerink, 2005; Svensson et al., 1975) . The lack of effect of L-DOPA on LC and DRN basal activity may rely on the necessity to apply higher doses of the drug.
Despite not modifying the basal parameters, the used dose of L-DOPA was able to potentiate the effect of reboxetine or diminish the effect of fluoxetine in the LC, likely through different mechanisms. Probably because exogenously administrated L-DOPA gives rise to noradrenaline in the LC, concomitant administration of L-DOPA and reboxetine significantly enhanced the inhibitory response to the antidepressant in the LC. In fact, exogenously administered L-DOPA is immediately decarboxylated to dopamine, which is then further transformed into noradrenaline in neurons that contain dopamine-b-hydroxylase. This noradrenaline might not have been sufficient to induce an effect per sé, but in combination with reboxetine the antidepressant effect was augmented. Reboxetine blocks noradrenaline transporters and inhibits the firing rate of neurons in the LC by increasing the concentration of noradrenaline. Because L-DOPA and reboxetine were administered together, the additive increase in noradrenaline in the LC likely caused a quicker inhibition of the neuron activity. In support of this idea, previous work from our group demonstrated that a low dose of reboxetine potentiates the inhibitory effect of noradrenaline in the LC (Grandoso et al., 2004) . Supportive studies have reported that the co-administration of noradrenaline with desipramine enhances the effect of noradrenaline both in vitro and in vivo (Curet et al., 1992; Williams et al., 1985) . Additionally, L-DOPA binds a 2 -adrenoceptors present in the LC (Alachkar et al., 2010) , what could explain, at least in part, the potentiated effect obtained when L-DOPA and reboxetine are administered together. In contrast, L-DOPA attenuated the effect of fluoxetine on LC cells. Previously, we have demonstrated that the effect of fluoxetine on LC cells is mediated by noradrenaline and a 2 adrenoceptors and that projecting neurons must be involved in this effect as it is absent in brain slices (Miguelez et al., 2009) . Because serotonergic projecting neurons may intervene in this mechanism, administering L-DOPA should attenuate the effects of fluoxetine acting at serotonergic terminal level. In fact, several evidences suggest that endogenous serotonin is replaced by L-DOPA derived dopamine, which can act as false neurotransmitter and diminish the effect of serotonin. In this sense, serotonin levels decrease after L-DOPA injection Commissiong and Sedgwick, 1979; Everett and Borcherding, 1970; Navailles et al., 2010a) and chronic administration of oral L-DOPA reduces serotonin levels (Borah and Mohanakumar, 2007) and excretions (Garcia et al., 1999) . In support of this, it is now well known that serotonergic neurons are responsible for the ectopic release of dopamine induced by L-DOPA being able to transform, store and release L-DOPA derived dopamine (Navailles et al., 2010b) . The presence of aromatic amino-acid decarboxylase and the vesicular monoamine transporter 2 in serotonergic neurons makes it feasible (Michelsen et al., 2007) . This fact has been proved both in parkinsonian animals (Carta et al., 2007; Navailles et al., 2010a; Tanaka et al., 1999; Yamada et al., 2007) and intact rats (Arai et al., 1994 (Arai et al., , 1995 (Arai et al., , 1996a (Arai et al., , 1996b . Coadministration of L-DOPA and fluoxetine can therefore lead to competition for the mechanisms involved in clearing or storing dopamine and serotonin. Another explanation for the observed interaction between the two drugs is that L-DOPA and fluoxetine have opposite effects on the same receptors. While both fluoxetine and dopamine bind 5-HT 2C serotonin receptors, the former acts as an antagonist (Koch et al., 2002; Millan et al., 1998; Palvimaki et al., 1996) , and the latter as an agonist (Oz et al., 2003; Woodward et al., 1992) , which could cause the effect of the antidepressant to be attenuated by L-DOPA. In the DRN, co-administration of L-DOPA with reboxetine or fluoxetine did not modify the inhibitory effect of both drugs on the serotonergic cells. The DRN receives a dense dopaminergic innervation from midbrain dopaminergic neurons (Kitahama et al., 2000; Peyron et al., 1998) and also contains high levels of D2-like and low levels of D1-like dopaminergic receptors (Bouthenet et al., 1987; Mansour et al., 1990; Suzuki et al., 1998) , dopamine (Ferre et al., 1994) and dopaminergic neurons (Miachon et al., 1984; Trulson et al., 1985; Yoshida et al., 1989) . Overall, it is still unclear whether dopamine or dopaminergic agents affect the DRN. However, the results of this study support our previous study Table 2 The effect of the co-administration of both antidepressants and L-DOPA on the spontaneous locomotor activity. L6 and L12 designate specific doses of L-DOPA (L6: 6 mg/kg of L-DOPA þ 15 mg/kg of benserazide, L12: 12 mg/kg of L-DOPA þ 15 mg/kg benserazide). The data are expressed as means AE S.E.M. of (n) animals during the 5-min testing period. #: p < 0.05 and ###: p < 0.001 when compared with saline treatment (one-way ANOVA followed by a Dunnett post hoc test for reboxetine and an unpaired Student's t-test for fluoxetine) *: p < 0.05, **: p < 0.01 and ***: p < 0.001 when compared with the corresponding reboxetine-alone treatment group (one-way ANOVA followed by Dunnett post hoc test). where the neuronal response to fluoxetine was unaltered in the DRN after nigro-striatal degeneration (Miguelez et al., 2011b) . As commented above, the difference between the influence of L-DOPA on the LC and DRN may rely on the conversion of L-DOPA derived dopamine into noradrenaline. In fact, the LC is a rich area in dopamine-b-hydroxylase, while in the DRN this enzyme is lesser expressed and it has been described only in the vicinity of the nucleus (Baldo et al., 2003) .
Behavioural impact of concomitant administration of L-DOPA and antidepressants
The finding that the administration of reboxetine decreased immobility and increased climbing behaviour in the mFST corroborates previous studies Harkin et al., 1999; Page et al., 2003) which postulate that this antidepressant behaviour results from the increase in noradrenaline levels in the frontal cortex (Page et al., 2003; Page and Lucki, 2002) . The interaction of the noradrenergic and dopaminergic systems has been widely demonstrated (El Mansari et al., 2010) . Previous studies have indicated that reboxetine increases both noradrenaline and dopamine levels in the frontal cortex (Dekeyne et al., 2001; Kitaichi et al., 2004; Page and Lucki, 2002; Sacchetti et al., 1999) . Similarly, L-DOPA can increase both dopamine (Eltayb et al., 2005; Loeffler et al., 1998) and noradrenaline levels in the cortex (Constantinidis et al., 1968) . Dopamine can be co-released with noradrenaline from noradrenergic nerve terminals (Devoto et al., 2001 (Devoto et al., , 2004 (Devoto et al., , 2005 , and noradrenaline transporters can also transport dopamine (Horn, 1973; Raiteri et al., 1977) . In the cortex, L-DOPA-derived dopamine can compete with noradrenaline for reuptake sites, and noradrenaline levels can remain increased longer before the neurotransmitter is metabolised. This interaction between dopamine and noradrenaline might underlie the potentiated antidepressantlike effect observed when reboxetine and L-DOPA were coadministered. Another possibility is that the L-DOPA-derived dopamine was converted into noradrenaline in the prefrontal cortex, which is supported by the observation that local administration of dopamine into the prefrontal cortex can increase extracellular noradrenaline concentrations (Pan et al., 2004) . The cortical release of noradrenaline produced from L-DOPA would potentiate the effects of reboxetine and cause non-effective doses of the antidepressant to become effective.
The finding that the sub-acute administration of fluoxetine produced a decrease in immobility and an increase in the swimming behaviour in the mFST is supported by previous studies (Detke et al., 1995; Page et al., 1999) . The mechanism underlying these behavioural changes likely involves changes in the extracellular levels of serotonin in the lateral septum (Kirby and Lucki, 1997) . Moreover, it seems unlikely that the blockade of the antidepressant effect of fluoxetine is the solely result of the competition between a predominant behaviour because climbing is not increased in expense of swimming. As extensively described above, several findings have characterised interactions between the serotonin and dopamine systems that may explain why the antidepressant effect of fluoxetine is blocked when the drug is co-administered with L-DOPA. This effect was revealed with 6 but not 12 mg/kg of L-DOPA. The raison why this blockage was observed at lower doses of L-DOPA require further investigation and may involve different mechanisms. In this line, a recent publication has reported that 20 mg/kg of fluoxetine administered together with 6 mg/kg of L-DOPA to parkinsonian animals attenuates L-DOPA's beneficial effects on motor performance while lower doses of the antidepressant with the same dosage of L-DOPA improved it (Bishop et al., 2012) .
Interaction between serotonergic and catecholaminergic systems is supported by the analysis of immobility and active behaviours. Immobility score, the classical parameter used, showed that reboxetine-L-DOPA combination reduced it but the contrary effect was seen for fluoxetine-L-DOPA. The analysis of the predominant active behaviours may inform about the underlying mechanisms. In the case of reboxetine-L-DOPA this might be a summation of the catecholaminergic activity because climbing behaviour is increased, accordingly with the electrophysiological data.
Conclusion
In conclusion, we have used both electrophysiological and behavioural studies to demonstrate that L-DOPA potentiates the effect of reboxetine but attenuates the effect of fluoxetine. Two main conclusions can be extracted from this work. On the one hand, adding L-DOPA to the pharmacological treatment with NRI can be a useful augmentation strategy for those patients that fail to respond properly to the medication. On the other hand, the concomitant use of L-DOPA with SSRI may deteriorate the therapeutic effect of the antidepressant. L-DOPA can therefore be useful for augmenting the response to NRI but this beneficial effect cannot be applied to SSRI. This work provides new knowledge on the interaction between antidepressants and L-DOPA, which may contribute in developing clinical augmentation therapies for treatment of drug-resistant depression.
